Finding new therapies for unmet needs in pet health inspires us every day

Watch Our Story

About Us


Aratana Therapeutics is a pioneer in pet therapeutics focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Aratana means “new beginning” and it defines our mission of developing safe and effective therapeutics for unmet or underserved medical conditions in pets. Our goal is to provide veterinarians and pet owners with new therapeutics that are driven by science and specifically made for pets. We believe pets are family and they deserve the best quality care.

Historically, there has been a lack of resources available to develop medical treatments for pets with chronic diseases. Progress in veterinary medicine lags years behind the scientific breakthroughs seen in human health.

Download our Corporate Brochure

This innovation gap between human science and veterinary medicine was the primary reason Aratana Therapeutics was founded in 2010, in the heart of the Kansas City Animal Health Corridor. The vision of the Company was and still is to find the best human drug development opportunities and apply them to veterinary medicine, specifically to advance therapeutics for pets – a new type of animal health company.

Now, experts with decades of experience in human health, animal health, biotechnology and other functional areas, paired with a lifelong love for pets, have been brought together. The entire team is committed to helping raise the standard of care for pets in order to help extend and improve the lives of cats and dogs. We have the pleasure of coming to work every day and putting our passion into making a difference for pets.

Our dedication has led us to develop a pipeline of novel therapeutics. We are focusing efforts in the areas of osteoarthritis, post-operative pain management, inappetence, allergy, lymphoma and osteosarcoma, viral diseases and other unmet pet health needs.


Related News Posts

Aratana, Elanco Announce Global Strategic Collaboration

Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced a licensing agreement for Aratana’s FDA-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs.